Mirum Pharmaceuticals (MIRM) Consolidated Net Income (2019 - 2026)
Mirum Pharmaceuticals' quarterly Consolidated Net Income came in at -$790.2 million in Q1 2026, down 5283.63% year-on-year from $15.2 million in Q1 2025, and down 13689.79% quarter-over-quarter from -$5.7 million in Q4 2025.
Mirum Pharmaceuticals has reported Consolidated Net Income for 8 years, with the latest figure at -$790.2 million in Q1 2026.
- For the quarter ending Q1 2026, Consolidated Net Income fell 5283.63% year-over-year to -$790.2 million; the trailing twelve-month figure through Mar 2026 stood at -$798.8 million (down 932.9% YoY), and the FY2025 full-year result was -$23.4 million, up 73.43% from the prior year.
- Consolidated Net Income for Q1 2026 stood at -$790.2 million, down from -$5.7 million in the prior quarter.
- The five-year high for Consolidated Net Income was $2.9 million in Q3 2025, with the low at -$790.2 million in Q1 2026.
- Average Consolidated Net Income over 5 years is -$70.6 million, with a median of -$25.3 million recorded in 2024.
- Year-over-year, Consolidated Net Income soared 120.41% in 2025 and sank 5283.63% in 2026.
- Tracing MIRM's Consolidated Net Income over 5 years: stood at -$36.4 million in 2022, then rose by 2.12% to -$35.7 million in 2023, then soared by 33.28% to -$23.8 million in 2024, then jumped by 75.91% to -$5.7 million in 2025, then tumbled by 13689.79% to -$790.2 million in 2026.
- The last three Consolidated Net Income figures came in at -$790.2 million (Q1 2026), -$5.7 million (Q4 2025), and $2.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Mirum Pharmaceuticals | 5.97 Bn | 5.59 Bn | 131.08 Mn | -790.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -790.16 Mn |
| Dec 31, 2025 | -5.73 Mn |
| Sep 30, 2025 | 2.91 Mn |
| Jun 30, 2025 | -5.86 Mn |
| Mar 31, 2025 | -14.68 Mn |
| Dec 31, 2024 | -23.79 Mn |
| Sep 30, 2024 | -14.24 Mn |
| Jun 30, 2024 | -24.64 Mn |
| Mar 31, 2024 | -25.28 Mn |
| Dec 31, 2023 | -35.66 Mn |
| Sep 30, 2023 | -23.59 Mn |
| Jun 30, 2023 | -74.04 Mn |
| Mar 31, 2023 | -30.13 Mn |
| Dec 31, 2022 | -36.43 Mn |
| Sep 30, 2022 | -35.71 Mn |
| Jun 30, 2022 | -26.92 Mn |
| Mar 31, 2022 | -36.61 Mn |
| Dec 31, 2021 | 57.55 Mn |
| Sep 30, 2021 | -47.11 Mn |
| Jun 30, 2021 | -43.89 Mn |
| Mar 31, 2021 | -50.53 Mn |
| Dec 31, 2020 | 66.17 Mn |
| Sep 30, 2020 | -21.51 Mn |
| Jun 30, 2020 | -23.25 Mn |
| Mar 31, 2020 | -21.31 Mn |
| Dec 31, 2019 | -18.07 Mn |
| Sep 30, 2019 | -15.09 Mn |
| Jun 30, 2019 | -13.56 Mn |
| Mar 31, 2019 | -5.96 Mn |